Key Takeaways
- • Octozi, a New York-based clinical data management startup, raised $3 million in seed funding led by Surface Ventures, with Remarkable Ventures as a co-investor, following an earlier undisclosed pre-seed round from Debiopharm's venture arm.
- • A Swiss pharmaceutical company (Debiopharm) secured a position on Octozi's cap table before any U.S. venture capital firm, signaling early European pharma sector recognition of the startup's solution for clinical trial data management.
- • Octozi addresses a critical pain point in pharmaceutical operations: the manual, inefficient data cleaning processes that currently rely heavily on spreadsheets, contract research organizations, and manual labor in clinical trials.
- • The funding sequence—European pharma pre-seed followed by U.S. venture backing—reflects a shift in early-stage biotech investment patterns, with strategic corporate investors from the pharmaceutical industry moving ahead of traditional venture capital.
- • Debiopharm Innovation Fund has formally added Octozi to its portfolio, positioning the startup as a core solution for addressing inefficient clinical trial data management within the broader pharmaceutical ecosystem.
Summary
Octozi, a clinical data management startup based in New York, has secured $3 million in seed funding led by Surface Ventures, with Remarkable Ventures participating in the round. The funding announcement follows an earlier, undisclosed pre-seed investment from Debiopharm Innovation Fund, the venture arm of Swiss pharmaceutical firm Debiopharm, marking a notable sequence in the startup's capital formation: European pharma backing preceded U.S. venture capital involvement.
The startup's core value proposition targets a fundamental operational inefficiency within the pharmaceutical industry. Clinical trial data management remains heavily dependent on manual processes, spreadsheets, and contract research organizations (CROs), creating bottlenecks in trial execution and regulatory compliance. According to founder commentary shared with Tech Funding News, Amit Patel highlighted that this process "still relies heavily on people, contract research organisations, and spreadsheets," underscoring the magnitude of the operational challenge Octozi aims to solve.
Debiopharm's early investment is strategically significant, as it positions a European pharmaceutical company ahead of established U.S. venture investors on Octozi's cap table. Debiopharm Innovation Fund has formally incorporated Octozi into its portfolio, identifying the startup as a solution to "one of Debiopharm and pharma's core pain points: inefficient, manual data cleaning in clinical trials." This placement reflects a broader trend in which pharmaceutical industry stakeholders are directly investing in early-stage technology companies addressing their operational challenges, rather than waiting for venture-backed solutions to mature.
The funding structure—combining strategic pharma backing with U.S. venture capital—positions Octozi to scale its data management infrastructure while benefiting from both industry domain expertise and growth capital. The startup's founding team includes Matt Purri, PhD; Erik Deurell, MD, MBA; and Josh Schiffman, suggesting relevant clinical and technical credentials aligned with the problem domain.
The startup's core value proposition targets a fundamental operational inefficiency within the pharmaceutical industry. Clinical trial data management remains heavily dependent on manual processes, spreadsheets, and contract research organizations (CROs), creating bottlenecks in trial execution and regulatory compliance. According to founder commentary shared with Tech Funding News, Amit Patel highlighted that this process "still relies heavily on people, contract research organisations, and spreadsheets," underscoring the magnitude of the operational challenge Octozi aims to solve.
Debiopharm's early investment is strategically significant, as it positions a European pharmaceutical company ahead of established U.S. venture investors on Octozi's cap table. Debiopharm Innovation Fund has formally incorporated Octozi into its portfolio, identifying the startup as a solution to "one of Debiopharm and pharma's core pain points: inefficient, manual data cleaning in clinical trials." This placement reflects a broader trend in which pharmaceutical industry stakeholders are directly investing in early-stage technology companies addressing their operational challenges, rather than waiting for venture-backed solutions to mature.
The funding structure—combining strategic pharma backing with U.S. venture capital—positions Octozi to scale its data management infrastructure while benefiting from both industry domain expertise and growth capital. The startup's founding team includes Matt Purri, PhD; Erik Deurell, MD, MBA; and Josh Schiffman, suggesting relevant clinical and technical credentials aligned with the problem domain.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.